Inarigivir ORI-9020; SB-9000|cas:475650-36-3|西域试剂

Inarigivir ORI-9020; SB-9000

产品编号：Bellancom-101954| CAS NO：475650-36-3| 分子式：C₂₀H₂₆N₇O₁₀PS| 分子量：587.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101954		￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Inarigivir ORI-9020; SB-9000

产品介绍

Inarigivir (ORI-9020;SB-9000) 是一种二核苷酸抗病毒化合物，可显着减少表达乙型肝炎病毒转基因小鼠的 HBV DNA。Inarigivir (ORI-9020) 是 RIG-I 的激动剂，可激活细胞内的先天免疫。

生物活性

Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses.

体外研究

Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	100 mg/kg.
Administration:	IP, daily.
Result:	Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	100 mg/kg.
Administration:	IP, daily.
Result:	Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control.

性状

Solid

溶解性数据

In Vitro:

DMSO : 200 mg/mL (340.43 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7021 mL	8.5106 mL	17.0213 mL
5 mM	0.3404 mL	1.7021 mL	3.4043 mL
10 mM	0.1702 mL	0.8511 mL	1.7021 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
2.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
3.

请依序添加每种溶剂： 1% DMSO 99% saline
Solubility: ≥ 0.25 mg/mL (0.43 mM); Clear solution